Media coverage about Agile Therapeutics (NASDAQ:AGRX) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agile Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 44.8515042055316 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
AGRX has been the topic of a number of research analyst reports. HC Wainwright set a $8.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $8.00 target price on shares of Agile Therapeutics in a research note on Monday, November 20th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $10.00 price target on shares of Agile Therapeutics in a report on Wednesday, October 18th. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. Finally, William Blair cut shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $9.20.
Shares of Agile Therapeutics (AGRX) opened at $3.27 on Wednesday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a 1-year low of $1.93 and a 1-year high of $5.60. The company has a market cap of $114.87, a P/E ratio of -3.55 and a beta of 2.01.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. analysts expect that Agile Therapeutics will post -0.97 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/31/agile-therapeutics-agrx-getting-somewhat-positive-press-coverage-study-shows.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.